Latest

COVID-19

·April 8, 2020·3 min read

Periodic physical distancing for COVID-19 control: New modeling study

Mathematical model incorporated several strategies to help flatten the COVID-19 curve, focusing on scarcity in hospital resources over two years. The models showed current physical distancing can help maintain healthcare capacity and reduce infections. The model also allowed for periodic economic and psychological breaks from social restrictions.

Featured Neuroscience Open Neuroscience Articles

·April 8, 2020·1 min read

Potential harms of chloroquine, hydroxychloroquine and azithromycin for treating COVID-19

Study warns of the potentially serious adverse effects of prescribing hydroxychloroquine and azithromycin for the treatment of COVID-19. Some of the potential side effects include cardiac arrhythmias, hypoglycemia, and neuropsychiatric effects.

Featured Neuroscience

·April 8, 2020·4 min read

Common coronaviruses are highly seasonal, with most cases peaking in winter months

Common coronaviruses are usually detected between December and May, with a peak of infection during January and February. Only 2.5% of cases occurred in the summer months. Researchers caution it is still too early to tell if COVID-19 will follow the same seasonal path as other coronaviruses.

Featured Neuroscience Open Neuroscience Articles

·April 8, 2020·1 min read

COVID-19: Anti-parasitic drug Ivermectin eliminates SARS-CoV-2 in cells in 48 hours

An FDA-approved anti-parasitic drug called Ivermectin appears to inhibit and eliminate SARS-CoV-2 in lab-grown cell cultures within 48 hours. Ivermectin shows promise as potential COVID-19 therapy. However, researchers stress the need for further testing and clinical trials in humans to confirm the effectiveness of the drug and appropriate dosage levels.

Featured Neuroscience Open Neuroscience Articles

·April 7, 2020·4 min read

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine

Researchers have developed a new vaccine that fully protects mice against MERS by using a harmless virus to deliver MERS-CoV into cells and generate an immune response. The vaccine is an innocuous parainfluenza virus (PIV5) which carries the spike protein MERS uses to infect cells. Findings show the PIV5 based vaccine could be a useful platform for COVID-19.

Featured Genetics Neuroscience

·April 7, 2020·5 min read

Coronavirus receptor abundantly expressed in certain progenitor cells

Certain progenitor cells in the bronchi are mainly responsible for producing coronavirus receptors. These cells normally develop into respiratory tract sells linked with cilia, that clear bacteria out of the lungs.

Featured Neuroscience Open Neuroscience Articles

·April 7, 2020·3 min read

COVID-19: Scientists find promising first step in antiviral treatment

Biological sequencing of the fusion peptides of SARS-CoV and SARS-CoV-2 found them to be a 93% match. Calcium ions interacting with the fusion peptide alters the peptide's structure, and how it interacts with membranes to promote infection. The findings provide a potential target for antiviral development to treat coronavirus.

Featured Neuroscience Open Neuroscience Articles

·April 7, 2020·3 min read

Could vitamin D help in fight against COVID-19?

Study reveals vitamin D could help to boost the immune system response and has been shown to help prevent other respiratory infections.

Featured Neuroscience Neuroscience Videos

·April 7, 2020·5 min read

Interstate Transmission of COVID-19 Is Now Most Urgent Threat

Domestic spread of coronavirus transmission via interstate travel is now more of a threat to people in American than from international travel. Findings repeat the need for more widespread diagnostic testing for COVID-19 at the state level and more intense tracking of people exposed to SARS-CoV-2.

Featured Genetics Neuroscience Open Neuroscience Articles

·April 6, 2020·3 min read

Reverse genetic system could accelerate coronavirus research and vaccine development

Using a reverse genetics system, researchers have engineered a labeled version of the SARS-CoV-2, which turns cells green when they become infected with the virus. The technology can significantly help reduce the length of time needed to evaluate developing COVID-19 vaccines and bring them to market sooner.

Featured Neuroscience

·April 6, 2020·3 min read

Anti-clotting drug could reduce ARDS deaths as a result of COVID-19

A new clinical trial is being established to see if anti-clotting drugs, commonly used for heart attack and stroke patients, can help treat COVID-19 patients who develop ARDS. If successful, the tPA drugs could help alleviate the expected ventilator shortage problem we are likely to experience soon.